Healio: Glecaprevir/pibrentasvir highly effective for treating HCV genotype 1

January 25, 2017

Glecaprevir/pibrentasvir was highly effective and well tolerated for the treatment of hepatitis C virus genotype 1 infection in patients who previously failed treatment with direct-acting antivirals, according to the results of the phase 2 open-label MAGELLAN-1 study. Read the full story at Healio


Rivard Report: Pilgrim Returns as Baptist Health System CEO

January 25, 2017

Describing San Antonio as a growing community and an important healthcare market, Trip Pilgrim returned to town and to the Baptist Health System this week as chief executive officer, a position he held from 2005-2009. Read the full report at the Rivard Report